Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma

Sridhar Mani, David Sciortino, Brian Samuels, Rose Arrietta, Richard L. Schilsky, Everett E. Vokes, Steven Benner

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Precis: UFT 300 mg/m2/day and leucovorin 90 mg/day could be administered safely to patients with advanced biliary cancer with good performance status; however, this combination and schedule of 28-day administration has no activity in this disease. Purpose: To determine the activity and evaluate the toxicity of uracil and tegafur in a 4:1 molar concentration ratio (UFT; Bristol-Myers Squibb, Wallingford, CT) plus oral calcium leucovorin in the treatment of patients with advanced biliary (gallbladder and bile duct) carcinoma. Patients and methods: Thirteen patients with advanced measurable biliary carcinoma were enrolled onto the trial. All patients had a Karnofsky performance status ≥ 60%, platelet count ≥ 75,000/μL, total bilirubin ≤ 2.0 x institutional upper limit of normal but otherwise normal liver and kidney function profile and bidimensionally measurable disease by CT scan or ultrasound examination. None of these patients previously received cytotoxic chemotherapy or radiation therapy for advanced disease. Patients received 300 mg/m2/d UFT plus 90 mg/d leucovorin administered orally in divided daily doses every 8 hours for 28 days repeated every 35 days. Objective tumor response, the primary endpoint of this trial, was evaluated after two courses of therapy. Other endpoints included toxicity, time to progression, and overall survival. Results: All patients were evaluable for response and toxicity. No complete or partial responses were observed in this trial. Four patients had stable disease lasting 17, 30, 33, and 35 weeks, respectively. The median (range) time to progression and survival were 9 (1-35) and 28 (1-61) weeks, respectively. Treatment-related toxicity was mild with severe (grade 3 or 4) diarrhea seen in 2 (15%). Grade 3-4 hyperbilirubinemia (31%) and nausea/vomiting (31%) were observed and likely related to the underlying disease. Grade 1 and 2 toxic effects included mainly anorexia and fatigue. Conclusion: UFT 300 mg/m2/d plus oral leucovorin 90 mg/d administered for 28 days repeated every 35 days is ineffective in the treatment of advanced biliary carcinoma.

Original languageEnglish (US)
Pages (from-to)97-101
Number of pages5
JournalInvestigational New Drugs
Volume17
Issue number1
DOIs
StatePublished - 1999

Fingerprint

Tegafur
Uracil
Leucovorin
Carcinoma
Biliary Tract Neoplasms
Karnofsky Performance Status
Hyperbilirubinemia
Survival
Poisons
Anorexia
Therapeutics
Bile Ducts
Gallbladder
Platelet Count
Bilirubin
Nausea
Vomiting
Fatigue
Diarrhea
Appointments and Schedules

Keywords

  • Bile duct carcinoma
  • Biliary
  • Cholangiocarcinoma
  • Ftorafur
  • Leucovorin
  • Uracil

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Mani, S., Sciortino, D., Samuels, B., Arrietta, R., Schilsky, R. L., Vokes, E. E., & Benner, S. (1999). Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Investigational New Drugs, 17(1), 97-101. https://doi.org/10.1023/A:1006268018519

Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. / Mani, Sridhar; Sciortino, David; Samuels, Brian; Arrietta, Rose; Schilsky, Richard L.; Vokes, Everett E.; Benner, Steven.

In: Investigational New Drugs, Vol. 17, No. 1, 1999, p. 97-101.

Research output: Contribution to journalArticle

Mani, S, Sciortino, D, Samuels, B, Arrietta, R, Schilsky, RL, Vokes, EE & Benner, S 1999, 'Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma', Investigational New Drugs, vol. 17, no. 1, pp. 97-101. https://doi.org/10.1023/A:1006268018519
Mani, Sridhar ; Sciortino, David ; Samuels, Brian ; Arrietta, Rose ; Schilsky, Richard L. ; Vokes, Everett E. ; Benner, Steven. / Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. In: Investigational New Drugs. 1999 ; Vol. 17, No. 1. pp. 97-101.
@article{5261b3eccc80410eb4ac2395cc318809,
title = "Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma",
abstract = "Precis: UFT 300 mg/m2/day and leucovorin 90 mg/day could be administered safely to patients with advanced biliary cancer with good performance status; however, this combination and schedule of 28-day administration has no activity in this disease. Purpose: To determine the activity and evaluate the toxicity of uracil and tegafur in a 4:1 molar concentration ratio (UFT; Bristol-Myers Squibb, Wallingford, CT) plus oral calcium leucovorin in the treatment of patients with advanced biliary (gallbladder and bile duct) carcinoma. Patients and methods: Thirteen patients with advanced measurable biliary carcinoma were enrolled onto the trial. All patients had a Karnofsky performance status ≥ 60{\%}, platelet count ≥ 75,000/μL, total bilirubin ≤ 2.0 x institutional upper limit of normal but otherwise normal liver and kidney function profile and bidimensionally measurable disease by CT scan or ultrasound examination. None of these patients previously received cytotoxic chemotherapy or radiation therapy for advanced disease. Patients received 300 mg/m2/d UFT plus 90 mg/d leucovorin administered orally in divided daily doses every 8 hours for 28 days repeated every 35 days. Objective tumor response, the primary endpoint of this trial, was evaluated after two courses of therapy. Other endpoints included toxicity, time to progression, and overall survival. Results: All patients were evaluable for response and toxicity. No complete or partial responses were observed in this trial. Four patients had stable disease lasting 17, 30, 33, and 35 weeks, respectively. The median (range) time to progression and survival were 9 (1-35) and 28 (1-61) weeks, respectively. Treatment-related toxicity was mild with severe (grade 3 or 4) diarrhea seen in 2 (15{\%}). Grade 3-4 hyperbilirubinemia (31{\%}) and nausea/vomiting (31{\%}) were observed and likely related to the underlying disease. Grade 1 and 2 toxic effects included mainly anorexia and fatigue. Conclusion: UFT 300 mg/m2/d plus oral leucovorin 90 mg/d administered for 28 days repeated every 35 days is ineffective in the treatment of advanced biliary carcinoma.",
keywords = "Bile duct carcinoma, Biliary, Cholangiocarcinoma, Ftorafur, Leucovorin, Uracil",
author = "Sridhar Mani and David Sciortino and Brian Samuels and Rose Arrietta and Schilsky, {Richard L.} and Vokes, {Everett E.} and Steven Benner",
year = "1999",
doi = "10.1023/A:1006268018519",
language = "English (US)",
volume = "17",
pages = "97--101",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma

AU - Mani, Sridhar

AU - Sciortino, David

AU - Samuels, Brian

AU - Arrietta, Rose

AU - Schilsky, Richard L.

AU - Vokes, Everett E.

AU - Benner, Steven

PY - 1999

Y1 - 1999

N2 - Precis: UFT 300 mg/m2/day and leucovorin 90 mg/day could be administered safely to patients with advanced biliary cancer with good performance status; however, this combination and schedule of 28-day administration has no activity in this disease. Purpose: To determine the activity and evaluate the toxicity of uracil and tegafur in a 4:1 molar concentration ratio (UFT; Bristol-Myers Squibb, Wallingford, CT) plus oral calcium leucovorin in the treatment of patients with advanced biliary (gallbladder and bile duct) carcinoma. Patients and methods: Thirteen patients with advanced measurable biliary carcinoma were enrolled onto the trial. All patients had a Karnofsky performance status ≥ 60%, platelet count ≥ 75,000/μL, total bilirubin ≤ 2.0 x institutional upper limit of normal but otherwise normal liver and kidney function profile and bidimensionally measurable disease by CT scan or ultrasound examination. None of these patients previously received cytotoxic chemotherapy or radiation therapy for advanced disease. Patients received 300 mg/m2/d UFT plus 90 mg/d leucovorin administered orally in divided daily doses every 8 hours for 28 days repeated every 35 days. Objective tumor response, the primary endpoint of this trial, was evaluated after two courses of therapy. Other endpoints included toxicity, time to progression, and overall survival. Results: All patients were evaluable for response and toxicity. No complete or partial responses were observed in this trial. Four patients had stable disease lasting 17, 30, 33, and 35 weeks, respectively. The median (range) time to progression and survival were 9 (1-35) and 28 (1-61) weeks, respectively. Treatment-related toxicity was mild with severe (grade 3 or 4) diarrhea seen in 2 (15%). Grade 3-4 hyperbilirubinemia (31%) and nausea/vomiting (31%) were observed and likely related to the underlying disease. Grade 1 and 2 toxic effects included mainly anorexia and fatigue. Conclusion: UFT 300 mg/m2/d plus oral leucovorin 90 mg/d administered for 28 days repeated every 35 days is ineffective in the treatment of advanced biliary carcinoma.

AB - Precis: UFT 300 mg/m2/day and leucovorin 90 mg/day could be administered safely to patients with advanced biliary cancer with good performance status; however, this combination and schedule of 28-day administration has no activity in this disease. Purpose: To determine the activity and evaluate the toxicity of uracil and tegafur in a 4:1 molar concentration ratio (UFT; Bristol-Myers Squibb, Wallingford, CT) plus oral calcium leucovorin in the treatment of patients with advanced biliary (gallbladder and bile duct) carcinoma. Patients and methods: Thirteen patients with advanced measurable biliary carcinoma were enrolled onto the trial. All patients had a Karnofsky performance status ≥ 60%, platelet count ≥ 75,000/μL, total bilirubin ≤ 2.0 x institutional upper limit of normal but otherwise normal liver and kidney function profile and bidimensionally measurable disease by CT scan or ultrasound examination. None of these patients previously received cytotoxic chemotherapy or radiation therapy for advanced disease. Patients received 300 mg/m2/d UFT plus 90 mg/d leucovorin administered orally in divided daily doses every 8 hours for 28 days repeated every 35 days. Objective tumor response, the primary endpoint of this trial, was evaluated after two courses of therapy. Other endpoints included toxicity, time to progression, and overall survival. Results: All patients were evaluable for response and toxicity. No complete or partial responses were observed in this trial. Four patients had stable disease lasting 17, 30, 33, and 35 weeks, respectively. The median (range) time to progression and survival were 9 (1-35) and 28 (1-61) weeks, respectively. Treatment-related toxicity was mild with severe (grade 3 or 4) diarrhea seen in 2 (15%). Grade 3-4 hyperbilirubinemia (31%) and nausea/vomiting (31%) were observed and likely related to the underlying disease. Grade 1 and 2 toxic effects included mainly anorexia and fatigue. Conclusion: UFT 300 mg/m2/d plus oral leucovorin 90 mg/d administered for 28 days repeated every 35 days is ineffective in the treatment of advanced biliary carcinoma.

KW - Bile duct carcinoma

KW - Biliary

KW - Cholangiocarcinoma

KW - Ftorafur

KW - Leucovorin

KW - Uracil

UR - http://www.scopus.com/inward/record.url?scp=0032844186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032844186&partnerID=8YFLogxK

U2 - 10.1023/A:1006268018519

DO - 10.1023/A:1006268018519

M3 - Article

VL - 17

SP - 97

EP - 101

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -